KO73149

JAN 14 2009

Section 5

510(k) Summary

Sponsor:

Siemens Medical Solutions USA, Inc.,

Ultrasound Division 1230 Shorebird Way

Mountain View, California 94043

Contact Person:

Sheila.W. Pickering

Telephone:

(650) 965 5398

Fax:

(650) 943 7053

Submission Date:

September 29, 2008

Device Name:

Siemens Diagnostic Ultrasound Systems Arterial Health Package

Software

Common Name:

Diagnostic Ultrasound System Imaging Software

Classification:

Regulatory Class:

П

Review Category:

Tier II Radiology

Classification Panel: Ra

System, Imaging Processing; 21 CFR 892.2050; LLZ

A. Legally Marketed Predicate Devices

The modified software is substantially equivalent to the software cleared in K061980 and K071036.

B. Device Description:

The modified software features provide for the measurement of anatomical structures and for analysis packages that provide information.

C. Intended Use

The Arterial Health Package (AHP) software provides the physician with the capability to measure Intima Media Thickness and the option to reference normative tables that have been validated and published in peer-reviewed studies. The information is intended to provide the physician with an easily understood tool for communicating with patients regarding state of their cardiovascular system. This feature should be utilized according to the "ASE Consensus Statement; Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Association of Echocardiography; Carotid Intima-Media Thickness Task Force, Endorsed by the Society for Vascular Imaging".

D. Substantial Equivalence

The submission device is substantially equivalent to the predicate with regard to both intended use and technological characteristics.

E. Performance Data

The Arterial Health Package software has been verified and validated according to the company's design control process.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Siemens Medical Solutions USA, Inc. % Mr. Mark Job
Responsible Third Party Official
Regulatory Technology Services, LLC
1394 25th Street NW
BUFFALO MN 55313

JAN 14 2009

Re: K083149

Trade/Device Name: Arterial Health Package (AHP) software

Regulation Number: 21 CFR 892.2050

Regulation Name: Picture archiving and communications system

Regulatory Class: II Product Code: LLZ

Dated: December 26, 2008 Received: December 29, 2008

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding os substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	(240) 276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	(240) 276-0115
21 CFR 892.xxx	(Radiology)	(240) 276-0120
Other		(240) 276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufactures, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry.suppot/index.html.

anine M. Morris

Sincerely yours

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Section 4

Indications for Use

(Part 21 CFR 801 Subpart		(21 CFR 801 Subpart C) THIS LINE-CONTINUE ON ANOTHER PAGE II
Prescription UseX		Over-The-Counter Use (21 CFR 801 Subpart C)
·		
Society for Vascular I		Andrew Production Pass 1 6166, Enderson by
Disease and Evaluate	Cardiovascular Dise	ase Risk: A Consensus Statement from the Americ Intima-Media Thickness Task Force, Endorsed by
heir cardiovascular sy	ystem. This feature s	should be utilized according to the identify Subclinical Vascular
validated and publishe	ed in peer-reviewed s	studies. The information is intended to provide the or communicating with patients regarding state of
neasure Intima Media	Thickness and the	rare provides the physician with the capability to option to reference normative tables that have been
Indications For Use:		
Device Name:	Arterial Health P	Package (AHP) Software